PART I Item 1. B usiness. Overview We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system. We believe this approach has the potential to effectively control diseases with high unmet need that are driven by excessive complement activation. We currently have two marketed d...
Q2 FY2026 — expected 2026-08-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065179 | EDGAR | 122K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029507 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020614 | EDGAR | — |
| 2023-02-21 | 2022-12-31 | 0000950170-23-003438 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007606 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008800 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007350 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001193125-25-257374 | EDGAR | 30K words |
| 2025-07-31 | 2025-06-30 | 0000950170-25-100545 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-064976 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121062 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-088938 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053921 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057117 | EDGAR | — |
| 2023-07-31 | 2023-06-30 | 0000950170-23-035935 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017819 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022606 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015500 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007374 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134916 | EDGAR | 67K words |
| 2026-03-02 | 0001193125-26-084156 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010540 | EDGAR | — |
| 2025-07-01 | 0001193125-25-153429 | EDGAR | — |
| 2025-06-04 | 0001193125-25-134886 | EDGAR | — |
| 2025-04-21 | 0001193125-25-086304 | EDGAR | — |
| 2025-01-13 | 0001193125-25-005052 | EDGAR | — |
| 2024-08-08 | 0001193125-24-196465 | EDGAR | — |
| 2024-06-05 | 0001193125-24-155179 | EDGAR | — |
| 2024-05-14 | 0001193125-24-137743 | EDGAR | — |
97 total filings indexed. 68 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001492422 |
| Ticker | APLS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.apellis.com |
| Listed | 2017-11-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report